PRRT2 and diabetes mellitus: In-so-far as multi-PKC inhibition but not pan-PKC or multi-kinase inhibition may be desirable to prevent diabetes-induced tissue damage, studies with Ruboxistaurin are consequently difficult to interpret with respect to whether the touted mechanism was selectively or suitably tested.